ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 456

Effect of Local and Systemic CCR2 Blockade on Knee Hyperalgesia in a Mouse Model of Osteoarthritis

Shingo Ishihara1, Rachel E. Miller2, Richard J. Miller3 and Anne-Marie Malfait4, 1Internal Medicine, Rush University Medical Center, Chicago, IL, 2Biochemistry, Rush University Medical Center, Chicago, IL, 3Pharmacology/Medical Humanities and Bioethics, Northwestern University, Chicago, IL, 4Biochemistry & Rheumatology, Rush University Medical Center, Chicago, IL

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: osteoarthritis and pain

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Pain Mechanisms – Basic and Clinical Science Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Surgical destabilization of the medial meniscus (DMM) in the mouse knee results in slowly progressive osteoarthritis (OA), characterized by moderate joint damage by week 8 and severe joint damage by week 16 after surgery. Progressive joint damage is associated with pain-related behaviors, including knee hyperalgesia and mechanical allodynia in the ipsilateral hindpaw (Miller RE et al. PNAS, 2012).

Knee hyperalgesia occurs in the early stages of experimental OA, week 2-8 after DMM surgery (Miller RE et al. Arthr Rheum 2017). We have previously shown that C-C Chemokine Receptor 2 (CCR2) signaling plays a key role in persistence of mechanical allodynia in this model, but has no effect on joint damage (Miller RE et al. PNAS, 2012). Here, we aimed to assess the effect of CCR2 blockade on knee hyperalgesia in the early phase of the disease.

Methods:

DMM or sham surgery was performed on the right knee of 10-week old male C57BL/6 wild type (WT) or Ccr2 null mice. Two, 4, and 8 weeks after surgery (n= 4-12/time point), knee hyperalgesia was measured by Pressure Application Measurement (PAM), as described (Miller RE et al. Arthr Rheum, 2017).

To study the effect of systemic pharmacological blockade of CCR2, CCR2 antagonist (5mg/kg) (CCR2RA, RS504393, Tocris) or vehicle control (100% DMSO4) was injected intraperitoneally (i.p.), 4 or 8 weeks after surgery in WT mice. Knee hyperalgesia was assessed hourly for 3 hours after injection.

To study the effect of local CCR2 blockade in the knee, 5µL of CCR2RA (0.4mg/kg) (BMS CCR2 22, RD Systems) (n=4) or 5µL of vehicle control (50% EtOH) (n=3) were injected intra-articularly (IA) 7 weeks after DMM surgery in WT mice. Knee hyperalgesia was measured hourly for 4 hours.

In addition, MCP-1 (5µL of 100ng/µL), the ligand for CCR2, or vehicle control (5µL PBS in 0.1% BSA) were injected IA in the right knee of 10-week old naïve WT and Ccr2 null mice (n=4/group), and knee hyperalgesia was assessed up to 24 hours after injection.

Results:

WT mice developed knee hyperalgesia 2 weeks after DMM but not sham surgery, and this was maintained until week 8. In contrast, Ccr2 null DMM mice were protected from hyperalgesia up to week 8 (p<0.0001 at week 2, 4, and 8).

Systemically administered CCR2RA alleviated established hyperalgesia in WT mice, 4 and 8 weeks after DMM (p<0.0001 compared to vehicle). Likewise, IA injection of CCR2RA into the knee joint 7 weeks after DMM reversed hyperalgesia (p<0.05 compared to vehicle).

IA administration of MCP-1, but not vehicle, rapidly induced knee hyperalgesia in naïve WT mice (p<0.001 compared to vehicle control), but not in Ccr2 null mice.

Conclusion:

These findings suggest a role for MCP1-CCR2 signaling in the development of knee hyperalgesia after DMM surgery. Furthermore, the findings with IA injection of MCP-1 or CCR2RA suggest that the effect is mediated by CCR2 present in the intra-articular space and that CCR2 is important for early OA knee pain.


Disclosure: S. Ishihara, None; R. E. Miller, None; R. J. Miller, None; A. M. Malfait, None.

To cite this abstract in AMA style:

Ishihara S, Miller RE, Miller RJ, Malfait AM. Effect of Local and Systemic CCR2 Blockade on Knee Hyperalgesia in a Mouse Model of Osteoarthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/effect-of-local-and-systemic-ccr2-blockade-on-knee-hyperalgesia-in-a-mouse-model-of-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-local-and-systemic-ccr2-blockade-on-knee-hyperalgesia-in-a-mouse-model-of-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology